


PHARMACEUTICAL 2018

JUNIPER PHARMACEUTICALS INC Rank 43 of 349







PHARMACEUTICAL 2018

RealRate

JUNIPER PHARMACEUTICALS INC Rank 43 of 349

The relative strengths and weaknesses of JUNIPER PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of JUNIPER PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 498% points. The greatest weakness of JUNIPER PHARMACEUTICALS INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 275% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 379% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	35,973
Cost of Goods Sold	28,961
Intangible Assets	9,867
Liabilities, Current	16,340
Liabilities, Non-Current	3,368
Other Assets	151
Other Compr. Net Income	1,871
Other Expenses	2,450
Other Liabilities	0
Other Net Income	1,617
Property and Equipment	15,229
Research and Development	6,860
Revenues	49,979
Selling, General and Administrative Expense	15,385

Output Variable	Value in 1000 USD
Assets	61,220
Liabilities	19,708
Expenses	53,656
Stockholders Equity	41,512
Net Income	-2,060
Comprehensive Net Income	-1,124
Economic Capital Ratio	102%

